InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.110 -0.005 (-4.35%)+
Announcement
Release
29 Jun 2026 9:54AM
Price at Release
$0.115
Full Release
download
Summary
Lumos Diagnostics, a leader in rapid point-of-care diagnostic technologies, announced it received a cash refund of A$709,837 as part of the Australian Government’s Research and Development Tax Incentive for the financial year ending 30 June 2025. This rebate supports Lumos' ongoing R&D efforts to enhance its portable handheld and disposable reader technology platforms. These advancements are crucial for the detection of clinical biomarkers, improving test result interpretations, and integration with electronic medical records. The rebate underscores Lumos' commitment to innovation in diagnostic technologies, which has helped secure partnerships with companies like Hologic and Aptatek BioSciences.
Key Points
  • Lumos received a cash refund of A$709,837.
  • The refund is for the fiscal year ending 30 June 2025.
  • Funds are from the Australian Government’s R&D Tax Incentive.
  • Rebate supports R&D in portable diagnostic platforms.
  • Platforms enhance biomarker detection and result interpretation.
  • Lumos partners with Hologic and Aptatek BioSciences.
  • CEO Doug Ward emphasized the importance of innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.